Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hematopoietic Stem Cell Transplantation | 71 | 2024 | 5445 | 8.980 |
Why?
|
Hematologic Neoplasms | 32 | 2024 | 1832 | 8.160 |
Why?
|
Palliative Care | 65 | 2024 | 3490 | 6.300 |
Why?
|
Terminal Care | 36 | 2023 | 1694 | 6.290 |
Why?
|
Quality of Life | 93 | 2024 | 12788 | 4.810 |
Why?
|
Hospice Care | 15 | 2023 | 672 | 4.400 |
Why?
|
Caregivers | 29 | 2024 | 2098 | 4.270 |
Why?
|
Leukemia, Myeloid, Acute | 27 | 2023 | 3524 | 4.150 |
Why?
|
Graft vs Host Disease | 24 | 2024 | 2958 | 3.440 |
Why?
|
Neoplasms | 58 | 2024 | 21675 | 2.780 |
Why?
|
End Stage Liver Disease | 6 | 2020 | 314 | 2.350 |
Why?
|
Advance Care Planning | 13 | 2023 | 662 | 2.290 |
Why?
|
Gastrointestinal Neoplasms | 15 | 2023 | 991 | 2.150 |
Why?
|
Depression | 38 | 2024 | 7760 | 1.790 |
Why?
|
Anxiety | 26 | 2024 | 4288 | 1.780 |
Why?
|
Affect | 11 | 2019 | 1473 | 1.690 |
Why?
|
Hospitalization | 29 | 2024 | 10259 | 1.600 |
Why?
|
Transplantation Conditioning | 17 | 2023 | 1599 | 1.590 |
Why?
|
Adaptation, Psychological | 18 | 2024 | 2575 | 1.380 |
Why?
|
Liver Diseases | 5 | 2024 | 1253 | 1.190 |
Why?
|
Humans | 258 | 2024 | 743811 | 1.180 |
Why?
|
Stress Disorders, Post-Traumatic | 8 | 2021 | 4266 | 1.170 |
Why?
|
Myelodysplastic Syndromes | 7 | 2020 | 1352 | 1.130 |
Why?
|
Disabled Persons | 6 | 2021 | 1214 | 1.130 |
Why?
|
Digestive System Diseases | 3 | 2023 | 147 | 1.110 |
Why?
|
Patient Preference | 9 | 2020 | 889 | 1.110 |
Why?
|
Confusion | 2 | 2018 | 275 | 1.090 |
Why?
|
Hospices | 5 | 2020 | 265 | 1.090 |
Why?
|
Lymphoma, Non-Hodgkin | 3 | 2022 | 1381 | 1.070 |
Why?
|
Stress, Psychological | 10 | 2024 | 4245 | 1.050 |
Why?
|
Videotape Recording | 5 | 2022 | 352 | 1.030 |
Why?
|
Stem Cell Transplantation | 6 | 2022 | 1620 | 0.910 |
Why?
|
Cross-Sectional Studies | 22 | 2024 | 25032 | 0.890 |
Why?
|
Aged | 95 | 2023 | 163178 | 0.890 |
Why?
|
Social Support | 5 | 2021 | 2118 | 0.880 |
Why?
|
Middle Aged | 99 | 2024 | 213241 | 0.870 |
Why?
|
Lymphoma | 7 | 2023 | 1875 | 0.870 |
Why?
|
Prognosis | 33 | 2024 | 29052 | 0.850 |
Why?
|
Patient Acceptance of Health Care | 11 | 2023 | 3020 | 0.850 |
Why?
|
Decision Making | 12 | 2021 | 3887 | 0.850 |
Why?
|
Natural Language Processing | 5 | 2023 | 1041 | 0.840 |
Why?
|
Family | 5 | 2020 | 3144 | 0.820 |
Why?
|
Inpatients | 6 | 2024 | 2515 | 0.810 |
Why?
|
Resuscitation Orders | 3 | 2019 | 269 | 0.780 |
Why?
|
Burkitt Lymphoma | 1 | 2023 | 326 | 0.770 |
Why?
|
Information Literacy | 1 | 2020 | 10 | 0.770 |
Why?
|
Male | 117 | 2024 | 349776 | 0.730 |
Why?
|
Cardiopulmonary Resuscitation | 7 | 2019 | 980 | 0.720 |
Why?
|
Female | 119 | 2024 | 380020 | 0.700 |
Why?
|
Immunotherapy, Adoptive | 4 | 2024 | 1271 | 0.690 |
Why?
|
Needs Assessment | 4 | 2020 | 1146 | 0.680 |
Why?
|
Lung Neoplasms | 18 | 2022 | 13112 | 0.680 |
Why?
|
Multiple Myeloma | 4 | 2022 | 5185 | 0.680 |
Why?
|
Electronics | 1 | 2020 | 321 | 0.630 |
Why?
|
Leukemia | 4 | 2022 | 1509 | 0.620 |
Why?
|
Roseolovirus Infections | 1 | 2018 | 45 | 0.610 |
Why?
|
Pilot Projects | 15 | 2024 | 8316 | 0.610 |
Why?
|
Meningoencephalitis | 1 | 2018 | 78 | 0.600 |
Why?
|
Esophageal and Gastric Varices | 1 | 2019 | 207 | 0.600 |
Why?
|
Herpesvirus 6, Human | 1 | 2018 | 95 | 0.600 |
Why?
|
Lymphoma, Follicular | 1 | 2021 | 435 | 0.600 |
Why?
|
Patients | 4 | 2023 | 899 | 0.580 |
Why?
|
Goals | 3 | 2023 | 708 | 0.570 |
Why?
|
Self Efficacy | 1 | 2020 | 615 | 0.560 |
Why?
|
Fatigue | 5 | 2024 | 1530 | 0.560 |
Why?
|
Intensive Care Units | 6 | 2023 | 3679 | 0.560 |
Why?
|
Busulfan | 3 | 2017 | 263 | 0.560 |
Why?
|
Empathy | 1 | 2021 | 474 | 0.560 |
Why?
|
Hospital Mortality | 3 | 2019 | 5316 | 0.550 |
Why?
|
Adult | 67 | 2024 | 213889 | 0.550 |
Why?
|
Leukemia, Myeloid | 1 | 2019 | 707 | 0.540 |
Why?
|
Arabinonucleosides | 1 | 2015 | 35 | 0.530 |
Why?
|
Adenine Nucleotides | 1 | 2015 | 121 | 0.520 |
Why?
|
Transplantation, Autologous | 6 | 2023 | 2123 | 0.510 |
Why?
|
Medical Oncology | 7 | 2021 | 2267 | 0.510 |
Why?
|
Attitude | 2 | 2020 | 775 | 0.500 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2018 | 355 | 0.500 |
Why?
|
Patient Care Planning | 2 | 2019 | 915 | 0.490 |
Why?
|
Patient Readmission | 4 | 2022 | 3117 | 0.480 |
Why?
|
Transplantation, Homologous | 10 | 2023 | 4777 | 0.480 |
Why?
|
Decision Support Techniques | 4 | 2020 | 1956 | 0.470 |
Why?
|
Trust | 1 | 2018 | 505 | 0.470 |
Why?
|
Communicable Disease Control | 1 | 2021 | 856 | 0.470 |
Why?
|
Physician-Patient Relations | 6 | 2020 | 3229 | 0.460 |
Why?
|
Delirium | 2 | 2023 | 1611 | 0.460 |
Why?
|
Aged, 80 and over | 28 | 2022 | 57744 | 0.460 |
Why?
|
Disease Susceptibility | 1 | 2020 | 1781 | 0.440 |
Why?
|
Glioma | 5 | 2022 | 3401 | 0.430 |
Why?
|
Immunocompromised Host | 1 | 2018 | 847 | 0.430 |
Why?
|
Longitudinal Studies | 8 | 2024 | 13980 | 0.430 |
Why?
|
Retrospective Studies | 28 | 2023 | 77410 | 0.420 |
Why?
|
Patient Satisfaction | 7 | 2024 | 3391 | 0.420 |
Why?
|
Monitoring, Physiologic | 1 | 2020 | 1738 | 0.410 |
Why?
|
Referral and Consultation | 4 | 2019 | 3530 | 0.410 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 6 | 2021 | 5230 | 0.400 |
Why?
|
Transplantation Immunology | 1 | 2013 | 546 | 0.390 |
Why?
|
Patient Education as Topic | 4 | 2022 | 2278 | 0.390 |
Why?
|
Head and Neck Neoplasms | 2 | 2022 | 2736 | 0.380 |
Why?
|
Prospective Studies | 18 | 2023 | 53250 | 0.380 |
Why?
|
Neoplasm Metastasis | 3 | 2019 | 4848 | 0.380 |
Why?
|
Central Nervous System Neoplasms | 4 | 2023 | 895 | 0.370 |
Why?
|
Intubation, Intratracheal | 2 | 2016 | 1365 | 0.360 |
Why?
|
Perception | 3 | 2022 | 1198 | 0.350 |
Why?
|
Length of Stay | 5 | 2022 | 6311 | 0.350 |
Why?
|
Sarcopenia | 3 | 2021 | 368 | 0.350 |
Why?
|
Communication | 10 | 2024 | 3748 | 0.330 |
Why?
|
Neurotoxicity Syndromes | 2 | 2023 | 290 | 0.330 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2021 | 2018 | 0.320 |
Why?
|
Patient Admission | 1 | 2016 | 1380 | 0.320 |
Why?
|
Hematology | 2 | 2023 | 221 | 0.320 |
Why?
|
Personal Satisfaction | 2 | 2024 | 641 | 0.320 |
Why?
|
Death | 3 | 2021 | 678 | 0.320 |
Why?
|
Health Communication | 2 | 2022 | 214 | 0.310 |
Why?
|
Liver Transplantation | 1 | 2019 | 2119 | 0.310 |
Why?
|
Antineoplastic Agents | 5 | 2019 | 13691 | 0.310 |
Why?
|
fms-Like Tyrosine Kinase 3 | 3 | 2016 | 491 | 0.310 |
Why?
|
Hematologic Diseases | 2 | 2023 | 498 | 0.310 |
Why?
|
Pancreatic Neoplasms | 2 | 2022 | 5264 | 0.300 |
Why?
|
Primary Myelofibrosis | 2 | 2023 | 215 | 0.300 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2019 | 2217 | 0.290 |
Why?
|
Treatment Outcome | 19 | 2021 | 63042 | 0.290 |
Why?
|
Patient Discharge | 3 | 2020 | 3317 | 0.280 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2015 | 1520 | 0.280 |
Why?
|
Randomized Controlled Trials as Topic | 9 | 2024 | 9944 | 0.280 |
Why?
|
United States | 20 | 2023 | 69859 | 0.270 |
Why?
|
Survivors | 4 | 2023 | 2291 | 0.260 |
Why?
|
Quality Improvement | 1 | 2020 | 3750 | 0.260 |
Why?
|
Bone Marrow Transplantation | 4 | 2020 | 2764 | 0.250 |
Why?
|
Breast Neoplasms | 7 | 2022 | 20827 | 0.250 |
Why?
|
Massachusetts | 6 | 2021 | 8660 | 0.240 |
Why?
|
Melanoma | 3 | 2021 | 5508 | 0.240 |
Why?
|
Attitude to Health | 3 | 2019 | 2052 | 0.240 |
Why?
|
Depressive Disorder | 1 | 2017 | 3744 | 0.230 |
Why?
|
Liver Neoplasms | 1 | 2019 | 4251 | 0.230 |
Why?
|
Physicians | 2 | 2019 | 4569 | 0.230 |
Why?
|
Niacinamide | 2 | 2016 | 416 | 0.220 |
Why?
|
Brain Neoplasms | 4 | 2023 | 8856 | 0.220 |
Why?
|
Patient Participation | 4 | 2020 | 1457 | 0.220 |
Why?
|
Disease Management | 4 | 2021 | 2459 | 0.220 |
Why?
|
Phenylurea Compounds | 2 | 2016 | 528 | 0.210 |
Why?
|
Critical Illness | 1 | 2015 | 2670 | 0.210 |
Why?
|
Bone Marrow | 3 | 2020 | 2951 | 0.210 |
Why?
|
Multicenter Studies as Topic | 2 | 2024 | 1676 | 0.200 |
Why?
|
Checklist | 2 | 2021 | 832 | 0.200 |
Why?
|
Human T-lymphotropic virus 1 | 1 | 2022 | 140 | 0.200 |
Why?
|
Health Knowledge, Attitudes, Practice | 5 | 2020 | 3921 | 0.200 |
Why?
|
Early Detection of Cancer | 5 | 2021 | 3089 | 0.190 |
Why?
|
Leukemia-Lymphoma, Adult T-Cell | 1 | 2022 | 166 | 0.190 |
Why?
|
Documentation | 3 | 2023 | 871 | 0.190 |
Why?
|
Activities of Daily Living | 5 | 2021 | 2419 | 0.190 |
Why?
|
Leucovorin | 1 | 2022 | 628 | 0.190 |
Why?
|
Acute Disease | 4 | 2020 | 7150 | 0.180 |
Why?
|
Chimerism | 1 | 2021 | 158 | 0.180 |
Why?
|
Emergency Service, Hospital | 1 | 2020 | 7658 | 0.180 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2022 | 297 | 0.180 |
Why?
|
Immunoconjugates | 2 | 2018 | 901 | 0.180 |
Why?
|
Wheelchairs | 1 | 2020 | 77 | 0.180 |
Why?
|
Mobility Limitation | 2 | 2021 | 409 | 0.180 |
Why?
|
Cytarabine | 2 | 2019 | 692 | 0.180 |
Why?
|
Telemedicine | 3 | 2022 | 2874 | 0.180 |
Why?
|
Combined Modality Therapy | 4 | 2020 | 8637 | 0.170 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2023 | 1596 | 0.170 |
Why?
|
Remission Induction | 4 | 2017 | 2384 | 0.170 |
Why?
|
Age Factors | 7 | 2020 | 18355 | 0.170 |
Why?
|
Ambulatory Care | 3 | 2022 | 2707 | 0.170 |
Why?
|
Cachexia | 1 | 2020 | 205 | 0.160 |
Why?
|
Long QT Syndrome | 1 | 2023 | 453 | 0.160 |
Why?
|
Qualitative Research | 5 | 2020 | 2682 | 0.160 |
Why?
|
Boston | 3 | 2021 | 9310 | 0.160 |
Why?
|
Evidence-Based Medicine | 3 | 2019 | 3608 | 0.160 |
Why?
|
Foscarnet | 1 | 2018 | 38 | 0.160 |
Why?
|
Psychometrics | 4 | 2021 | 3000 | 0.160 |
Why?
|
Graft vs Host Reaction | 1 | 2018 | 104 | 0.160 |
Why?
|
Young Adult | 12 | 2023 | 56392 | 0.150 |
Why?
|
Vaginal Smears | 1 | 2021 | 511 | 0.150 |
Why?
|
Respiration, Artificial | 2 | 2021 | 2568 | 0.150 |
Why?
|
T-Lymphocytes | 4 | 2024 | 10179 | 0.150 |
Why?
|
New England | 1 | 2020 | 1022 | 0.150 |
Why?
|
Fluorouracil | 1 | 2022 | 1619 | 0.150 |
Why?
|
Colorectal Neoplasms | 4 | 2021 | 6773 | 0.150 |
Why?
|
Tracheostomy | 1 | 2021 | 401 | 0.150 |
Why?
|
Socioeconomic Factors | 4 | 2021 | 7784 | 0.150 |
Why?
|
Efficiency | 1 | 2020 | 462 | 0.150 |
Why?
|
Survival Analysis | 4 | 2020 | 10251 | 0.150 |
Why?
|
Cord Blood Stem Cell Transplantation | 1 | 2019 | 314 | 0.140 |
Why?
|
Anthracyclines | 1 | 2019 | 288 | 0.140 |
Why?
|
Pandemics | 6 | 2022 | 8385 | 0.140 |
Why?
|
Chronic Disease | 3 | 2018 | 9139 | 0.140 |
Why?
|
Cohort Studies | 5 | 2022 | 40545 | 0.140 |
Why?
|
Attitude of Health Personnel | 3 | 2019 | 3839 | 0.140 |
Why?
|
Organ Specificity | 2 | 2020 | 2008 | 0.140 |
Why?
|
Myeloproliferative Disorders | 1 | 2022 | 606 | 0.140 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 5 | 2023 | 11524 | 0.140 |
Why?
|
Geriatric Assessment | 2 | 2023 | 1372 | 0.140 |
Why?
|
Self Report | 5 | 2022 | 3550 | 0.140 |
Why?
|
Bacteremia | 2 | 2020 | 963 | 0.140 |
Why?
|
Logistic Models | 4 | 2020 | 13404 | 0.140 |
Why?
|
Cultural Competency | 1 | 2019 | 289 | 0.130 |
Why?
|
Lymphoma, B-Cell | 1 | 2022 | 931 | 0.130 |
Why?
|
Actigraphy | 1 | 2019 | 488 | 0.130 |
Why?
|
Severity of Illness Index | 5 | 2020 | 15526 | 0.130 |
Why?
|
Monitoring, Ambulatory | 1 | 2019 | 358 | 0.130 |
Why?
|
Tandem Repeat Sequences | 1 | 2016 | 185 | 0.130 |
Why?
|
Feasibility Studies | 3 | 2023 | 5078 | 0.130 |
Why?
|
Immunotherapy | 2 | 2021 | 4437 | 0.130 |
Why?
|
Delivery of Health Care | 3 | 2024 | 5319 | 0.130 |
Why?
|
Physical Fitness | 1 | 2019 | 732 | 0.130 |
Why?
|
Waiting Lists | 1 | 2019 | 692 | 0.120 |
Why?
|
Decision Support Systems, Clinical | 2 | 2015 | 1164 | 0.120 |
Why?
|
Medication Adherence | 2 | 2023 | 2063 | 0.120 |
Why?
|
Religion | 1 | 2017 | 356 | 0.120 |
Why?
|
Autopsy | 1 | 2018 | 1020 | 0.120 |
Why?
|
Time Factors | 5 | 2019 | 40038 | 0.120 |
Why?
|
Regression Analysis | 2 | 2021 | 6457 | 0.120 |
Why?
|
Liver Cirrhosis | 2 | 2024 | 1859 | 0.120 |
Why?
|
Health Services Accessibility | 2 | 2021 | 5136 | 0.110 |
Why?
|
Continuity of Patient Care | 1 | 2020 | 1049 | 0.110 |
Why?
|
Odds Ratio | 4 | 2019 | 9848 | 0.110 |
Why?
|
Disease-Free Survival | 4 | 2017 | 6895 | 0.110 |
Why?
|
Video Recording | 2 | 2016 | 949 | 0.110 |
Why?
|
Fatal Outcome | 1 | 2018 | 1851 | 0.110 |
Why?
|
Emotions | 3 | 2020 | 2656 | 0.110 |
Why?
|
Follow-Up Studies | 7 | 2019 | 39001 | 0.110 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2022 | 2540 | 0.110 |
Why?
|
Respiratory Insufficiency | 1 | 2021 | 1199 | 0.110 |
Why?
|
Anemia, Sickle Cell | 1 | 2020 | 1020 | 0.110 |
Why?
|
Neoplasms, Second Primary | 1 | 2020 | 1063 | 0.110 |
Why?
|
Nursing Homes | 1 | 2019 | 1036 | 0.110 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2018 | 685 | 0.110 |
Why?
|
Heart Failure | 1 | 2016 | 10896 | 0.100 |
Why?
|
Managed Care Programs | 1 | 2018 | 950 | 0.100 |
Why?
|
Sexual Behavior | 2 | 2021 | 2049 | 0.100 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2019 | 1131 | 0.100 |
Why?
|
Blood Transfusion | 1 | 2018 | 1301 | 0.100 |
Why?
|
Protein Kinase Inhibitors | 3 | 2022 | 5532 | 0.100 |
Why?
|
Mutagenesis, Insertional | 1 | 2014 | 654 | 0.100 |
Why?
|
Uncertainty | 1 | 2016 | 735 | 0.100 |
Why?
|
Electronic Health Records | 4 | 2021 | 4467 | 0.100 |
Why?
|
Hospitals, Teaching | 1 | 2016 | 1180 | 0.100 |
Why?
|
Adolescent | 5 | 2024 | 85729 | 0.100 |
Why?
|
Terminology as Topic | 1 | 2018 | 1546 | 0.100 |
Why?
|
Models, Immunological | 1 | 2013 | 527 | 0.100 |
Why?
|
Signal Transduction | 2 | 2013 | 23398 | 0.100 |
Why?
|
Geriatrics | 1 | 2015 | 396 | 0.100 |
Why?
|
Sex Characteristics | 2 | 2018 | 2583 | 0.090 |
Why?
|
Research | 2 | 2017 | 1999 | 0.090 |
Why?
|
Consensus | 1 | 2019 | 2954 | 0.090 |
Why?
|
Exercise Therapy | 1 | 2017 | 904 | 0.090 |
Why?
|
Psychiatric Status Rating Scales | 2 | 2017 | 6030 | 0.090 |
Why?
|
Cyclophosphamide | 3 | 2023 | 2241 | 0.090 |
Why?
|
Pain | 3 | 2022 | 4987 | 0.090 |
Why?
|
Teaching | 1 | 2017 | 1173 | 0.090 |
Why?
|
Antidepressive Agents | 2 | 2020 | 2837 | 0.090 |
Why?
|
Interpersonal Relations | 1 | 2017 | 1424 | 0.090 |
Why?
|
Multivariate Analysis | 3 | 2019 | 12243 | 0.090 |
Why?
|
Mammography | 1 | 2021 | 2475 | 0.090 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2018 | 941 | 0.090 |
Why?
|
Weight Loss | 1 | 2021 | 2625 | 0.090 |
Why?
|
Survival Rate | 4 | 2018 | 12786 | 0.090 |
Why?
|
Databases, Factual | 3 | 2019 | 7729 | 0.090 |
Why?
|
Tissue Donors | 1 | 2019 | 2241 | 0.090 |
Why?
|
Neoplasm Invasiveness | 1 | 2017 | 3617 | 0.090 |
Why?
|
Radiotherapy, Computer-Assisted | 1 | 2009 | 94 | 0.080 |
Why?
|
Muscle, Skeletal | 2 | 2021 | 4925 | 0.080 |
Why?
|
Healthcare Disparities | 2 | 2021 | 3155 | 0.080 |
Why?
|
Body Composition | 1 | 2018 | 2401 | 0.080 |
Why?
|
Patient Selection | 1 | 2020 | 4210 | 0.080 |
Why?
|
Risk Factors | 3 | 2020 | 72252 | 0.080 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2023 | 9239 | 0.080 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2022 | 2200 | 0.080 |
Why?
|
Cause of Death | 1 | 2017 | 3580 | 0.070 |
Why?
|
Lung | 2 | 2023 | 9858 | 0.070 |
Why?
|
Analgesics, Opioid | 2 | 2022 | 3677 | 0.070 |
Why?
|
Clinical Trials as Topic | 1 | 2022 | 7908 | 0.070 |
Why?
|
Isocitrate Dehydrogenase | 2 | 2023 | 871 | 0.070 |
Why?
|
Kidney Failure, Chronic | 1 | 2019 | 2534 | 0.070 |
Why?
|
Societies, Medical | 1 | 2018 | 3740 | 0.070 |
Why?
|
Substance-Related Disorders | 1 | 2022 | 4254 | 0.070 |
Why?
|
Vidarabine | 2 | 2019 | 345 | 0.070 |
Why?
|
Therapeutics | 1 | 2006 | 116 | 0.070 |
Why?
|
Truth Disclosure | 1 | 2010 | 436 | 0.070 |
Why?
|
Diagnosis | 1 | 2006 | 154 | 0.070 |
Why?
|
Antiviral Agents | 1 | 2018 | 2984 | 0.070 |
Why?
|
Anxiety Disorders | 1 | 2016 | 2684 | 0.060 |
Why?
|
Cost of Illness | 3 | 2019 | 1859 | 0.060 |
Why?
|
Mass Screening | 1 | 2020 | 5251 | 0.060 |
Why?
|
Nanoparticles | 2 | 2007 | 1898 | 0.060 |
Why?
|
Educational Status | 3 | 2019 | 2540 | 0.060 |
Why?
|
Kidney Transplantation | 1 | 2019 | 4251 | 0.060 |
Why?
|
Health Personnel | 1 | 2017 | 3217 | 0.060 |
Why?
|
Dendrimers | 1 | 2004 | 68 | 0.060 |
Why?
|
Gold | 1 | 2007 | 485 | 0.060 |
Why?
|
Registries | 1 | 2019 | 8090 | 0.060 |
Why?
|
Gastrointestinal Tract | 2 | 2020 | 814 | 0.060 |
Why?
|
Internal Medicine | 1 | 2010 | 1009 | 0.050 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2023 | 288 | 0.050 |
Why?
|
Diagnosis, Differential | 1 | 2018 | 12954 | 0.050 |
Why?
|
Bereavement | 1 | 2006 | 278 | 0.050 |
Why?
|
Alzheimer Disease | 1 | 2023 | 8035 | 0.050 |
Why?
|
Self-Help Groups | 1 | 2023 | 190 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3134 | 0.050 |
Why?
|
Proportional Hazards Models | 1 | 2017 | 12354 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3241 | 0.050 |
Why?
|
Interviews as Topic | 2 | 2021 | 2538 | 0.050 |
Why?
|
Quality of Health Care | 1 | 2017 | 4370 | 0.050 |
Why?
|
Interdisciplinary Studies | 1 | 2021 | 89 | 0.050 |
Why?
|
Incidence | 4 | 2023 | 20948 | 0.050 |
Why?
|
Recurrence | 2 | 2023 | 8337 | 0.050 |
Why?
|
Neoplasm Staging | 3 | 2020 | 11036 | 0.050 |
Why?
|
Infant, Newborn | 1 | 2021 | 25609 | 0.050 |
Why?
|
Self-Help Devices | 1 | 2021 | 67 | 0.050 |
Why?
|
Mind-Body Therapies | 1 | 2023 | 247 | 0.050 |
Why?
|
Program Evaluation | 2 | 2020 | 2483 | 0.050 |
Why?
|
Ohio | 1 | 2021 | 337 | 0.050 |
Why?
|
Karnofsky Performance Status | 1 | 2020 | 173 | 0.040 |
Why?
|
Social Work | 1 | 2021 | 162 | 0.040 |
Why?
|
Guilt | 1 | 2020 | 95 | 0.040 |
Why?
|
Antigens, CD19 | 1 | 2022 | 380 | 0.040 |
Why?
|
Methotrexate | 2 | 2017 | 1726 | 0.040 |
Why?
|
New York | 1 | 2022 | 885 | 0.040 |
Why?
|
Knowledge | 1 | 2020 | 181 | 0.040 |
Why?
|
Pneumonia, Aspiration | 1 | 2019 | 145 | 0.040 |
Why?
|
Whole-Body Irradiation | 1 | 2019 | 449 | 0.040 |
Why?
|
Child | 3 | 2021 | 77637 | 0.040 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2013 | 3255 | 0.040 |
Why?
|
Ciprofloxacin | 1 | 2020 | 314 | 0.040 |
Why?
|
Dehydration | 1 | 2019 | 232 | 0.040 |
Why?
|
Guidelines as Topic | 2 | 2020 | 1404 | 0.040 |
Why?
|
Hinduism | 1 | 2017 | 14 | 0.040 |
Why?
|
Morals | 1 | 2021 | 284 | 0.040 |
Why?
|
Veterans Health | 1 | 2019 | 216 | 0.040 |
Why?
|
Buddhism | 1 | 2017 | 21 | 0.040 |
Why?
|
Melphalan | 1 | 2019 | 431 | 0.040 |
Why?
|
Judaism | 1 | 2017 | 30 | 0.040 |
Why?
|
Christianity | 1 | 2017 | 47 | 0.040 |
Why?
|
Thiotepa | 1 | 2017 | 66 | 0.040 |
Why?
|
Tissue and Organ Harvesting | 1 | 2020 | 369 | 0.040 |
Why?
|
Drug Tolerance | 1 | 2019 | 376 | 0.040 |
Why?
|
Suicide, Assisted | 1 | 2017 | 64 | 0.040 |
Why?
|
Employment | 1 | 2023 | 1132 | 0.040 |
Why?
|
Islam | 1 | 2017 | 69 | 0.040 |
Why?
|
Spleen | 1 | 2023 | 2359 | 0.040 |
Why?
|
Hawaii | 1 | 2016 | 105 | 0.030 |
Why?
|
Nitriles | 1 | 2021 | 953 | 0.030 |
Why?
|
Central Nervous System | 1 | 2023 | 1358 | 0.030 |
Why?
|
Professional-Family Relations | 1 | 2020 | 482 | 0.030 |
Why?
|
Mucositis | 1 | 2017 | 100 | 0.030 |
Why?
|
Risk Assessment | 1 | 2017 | 23327 | 0.030 |
Why?
|
Psychological Tests | 1 | 2018 | 647 | 0.030 |
Why?
|
Mental Health | 2 | 2022 | 3012 | 0.030 |
Why?
|
Mutation | 4 | 2021 | 29777 | 0.030 |
Why?
|
Dementia | 1 | 2009 | 2518 | 0.030 |
Why?
|
Antibiotic Prophylaxis | 1 | 2020 | 638 | 0.030 |
Why?
|
Maximum Tolerated Dose | 1 | 2017 | 892 | 0.030 |
Why?
|
Longevity | 1 | 2022 | 1070 | 0.030 |
Why?
|
Psychotherapy | 1 | 2023 | 1640 | 0.030 |
Why?
|
Glioblastoma | 1 | 2009 | 3480 | 0.030 |
Why?
|
Dacarbazine | 1 | 2017 | 566 | 0.030 |
Why?
|
Renal Insufficiency | 1 | 2019 | 805 | 0.030 |
Why?
|
Urinary Tract Infections | 1 | 2019 | 788 | 0.030 |
Why?
|
United States Food and Drug Administration | 1 | 2021 | 1582 | 0.030 |
Why?
|
Research Report | 1 | 2016 | 355 | 0.030 |
Why?
|
Cluster Analysis | 1 | 2020 | 2712 | 0.030 |
Why?
|
SEER Program | 1 | 2018 | 1507 | 0.030 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2016 | 781 | 0.030 |
Why?
|
Renal Dialysis | 1 | 2022 | 1783 | 0.030 |
Why?
|
Research Design | 2 | 2020 | 5983 | 0.030 |
Why?
|
Insurance Coverage | 1 | 2024 | 1900 | 0.030 |
Why?
|
Patient-Centered Care | 1 | 2022 | 1438 | 0.030 |
Why?
|
C-Reactive Protein | 1 | 2023 | 3778 | 0.030 |
Why?
|
Proxy | 1 | 2012 | 145 | 0.030 |
Why?
|
Tissue Distribution | 2 | 2007 | 2327 | 0.020 |
Why?
|
Syndrome | 1 | 2018 | 3249 | 0.020 |
Why?
|
Family Health | 1 | 2016 | 1280 | 0.020 |
Why?
|
Fear | 1 | 2020 | 1438 | 0.020 |
Why?
|
Adrenal Cortex Hormones | 1 | 2020 | 1854 | 0.020 |
Why?
|
Tacrolimus | 1 | 2015 | 743 | 0.020 |
Why?
|
Practice Guidelines as Topic | 2 | 2020 | 7270 | 0.020 |
Why?
|
Curriculum | 2 | 2017 | 3603 | 0.020 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2021 | 2039 | 0.020 |
Why?
|
Pyrazoles | 1 | 2021 | 1970 | 0.020 |
Why?
|
Aftercare | 1 | 2017 | 870 | 0.020 |
Why?
|
Motivation | 1 | 2020 | 1971 | 0.020 |
Why?
|
Illinois | 1 | 2010 | 119 | 0.020 |
Why?
|
Internship and Residency | 1 | 2010 | 5787 | 0.020 |
Why?
|
Pyrimidines | 1 | 2021 | 2945 | 0.020 |
Why?
|
Pain Measurement | 1 | 2019 | 3420 | 0.020 |
Why?
|
Health Promotion | 1 | 2021 | 2205 | 0.020 |
Why?
|
Bacterial Infections | 1 | 2017 | 1400 | 0.020 |
Why?
|
Postoperative Complications | 2 | 2022 | 15281 | 0.020 |
Why?
|
Graft Rejection | 1 | 2021 | 4398 | 0.020 |
Why?
|
Pneumonia | 1 | 2019 | 2133 | 0.020 |
Why?
|
Sirolimus | 1 | 2015 | 1565 | 0.020 |
Why?
|
Education | 1 | 2010 | 543 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2012 | 2971 | 0.020 |
Why?
|
Linear Models | 1 | 2016 | 5952 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2017 | 6539 | 0.020 |
Why?
|
Patient Care Team | 1 | 2017 | 2528 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2024 | 19894 | 0.020 |
Why?
|
Sepsis | 1 | 2019 | 2593 | 0.020 |
Why?
|
Comorbidity | 1 | 2019 | 10380 | 0.020 |
Why?
|
Animals | 3 | 2013 | 168660 | 0.020 |
Why?
|
Prostatic Neoplasms | 1 | 2007 | 11059 | 0.020 |
Why?
|
Exercise | 1 | 2021 | 5611 | 0.020 |
Why?
|
Terminally Ill | 1 | 2006 | 238 | 0.020 |
Why?
|
Opioid-Related Disorders | 1 | 2019 | 2064 | 0.010 |
Why?
|
Sex Factors | 1 | 2018 | 10394 | 0.010 |
Why?
|
Health Status | 1 | 2017 | 4031 | 0.010 |
Why?
|
Risk | 1 | 2016 | 9677 | 0.010 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2017 | 4477 | 0.010 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2017 | 2988 | 0.010 |
Why?
|
Particle Size | 1 | 2007 | 1639 | 0.010 |
Why?
|
Choice Behavior | 1 | 2009 | 802 | 0.010 |
Why?
|
Educational Measurement | 1 | 2010 | 1210 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2020 | 7172 | 0.010 |
Why?
|
Medicare | 1 | 2019 | 6565 | 0.010 |
Why?
|
Brachytherapy | 1 | 2009 | 1247 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2010 | 6356 | 0.010 |
Why?
|
Nuclear Proteins | 1 | 2016 | 5854 | 0.010 |
Why?
|
Mice, Nude | 1 | 2007 | 3680 | 0.010 |
Why?
|
Melanoma, Experimental | 1 | 2004 | 560 | 0.010 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2009 | 1624 | 0.010 |
Why?
|
Body Mass Index | 1 | 2018 | 12718 | 0.010 |
Why?
|
Radiosurgery | 1 | 2009 | 1331 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2018 | 20121 | 0.010 |
Why?
|
Clinical Competence | 1 | 2010 | 4687 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2007 | 16674 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2007 | 21824 | 0.010 |
Why?
|
Mice | 1 | 2007 | 81154 | 0.000 |
Why?
|